VALANX Biotech GmbH has appointed Klaus Orlinger as chief scientific officer to drive the Austrian company’s scientific strategy including development of its protein conjugation platform. Dr Orlinger joins VALANX from HOOKIPA Pharma where, as CSO, vice president research and head of virology, he played a key role in advancing multiple drug candidates in immuno-oncology and infectious disease from early research through phase 1 and 2 clinical studies in the US and EU. He holds a degree, masters and PhD in genetics and microbiology from the University of Vienna. VALANX is working to progress its first antibody drug conjugate to candidate selection phase and developing its technology for site-specific protein conjugation in drug discovery.
VALANX Biotech announced the appointment on 30 October 2025.
Copyright 2025 Evernow Publishing Ltd.